120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
ROS 响应性纳米包封硒通过 PI3K/AKT 信号通路靶向宫颈癌细胞
Authors Qiu Y , Hu C , Zhao S, Chen D, Shen J, Dai F, Ban M, Ma Y, Weng J, Huang X , Zhu Y, Zhao L, Guo F
Received 27 August 2025
Accepted for publication 29 January 2026
Published 7 February 2026 Volume 2026:21 558115
DOI https://doi.org/10.2147/IJN.S558115
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Yan Shen
Yanmei Qiu,1,2,* Chongke Hu,1,* Sifang Zhao,3,* Dezhi Chen,2 Jiaying Shen,1 Fanjia Dai,3 Mengxin Ban,3 Yimin Ma,3 Jingjing Weng,4 Xiaoping Huang,1 Yingying Zhu,4 Lingling Zhao,3 Fei Guo1,2
1Ningbo Institute of Innovation for Combined Medicine and Engineering (NIIME), The Affiliated LiHuili Hospital of Ningbo University, Ningbo, Zhejiang, 315100, People’s Republic of China; 2The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, 330006, People’s Republic of China; 3School of Materials Science and Chemical Engineering, Ningbo University, Ningbo, Zhejiang, 311215, People’s Republic of China; 4Department of Obstetrics and Gynecology, LiHuili Hospital Affiliated to Ningbo University, Ningbo, Zhejiang, 315040, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Fei Guo, Email lhlguofei@nbu.edu.cn Lingling Zhao, Email zhaolingling@nbu.edu.cn
Purpose: Current cervical cancer treatments have yet to realize significant advances in patient quality of life. To overcome the challenges of off-target toxicity and inefficient delivery, we developed targeted ROS-responsive selenium nanoparticles, based on selenium’s anticancer properties.
Methods: FA-ReRSeNPs were synthesized and subjected to systematic characterization of their physicochemical and biological properties. The anti-tumor activity of FA-ReRSeNPs, along with the mechanistic basis, was validated using integrated in vitro assays and in vivo animal models.
Results: Using human cervical cancer cells (Hela and SiHa) and a SiHa subcutaneous xenograft nude mouse model, we verified that FA-ReRSeNPs significantly reduced the selenium dose required for anticancer activity, while alleviating off-target damage to normal tissues. Mechanistic studies confirmed that FA-ReRSeNPs exert anticancer effects via inhibition of PI3K/AKT signaling pathway; this inhibition subsequently induces tumor cell apoptosis and restrains proliferation. Cross-validated results from in vitro assays and in vivo burden analyses demonstrate that FA-ReRSeNPs possess superior tumor-inhibitory potential with high targeting specificity.
Conclusion: This work confirms FA-ReRSeNPs as a precision-driven nanotherapeutic for cervical cancer management. The fusion of active targeting and ROS-responsive release mechanisms addresses the classic efficacy-toxicity dilemma of conventional anticancer agents, highlighting the translational value of intelligent nanoengineering in advancing cancer therapies.
Keywords: FA-ReRSeNPslenium, FA-ReRSeNPs, ROS-responsive delivery, cervical cancer, PI3K/AKT signaling pathway, targeted therapy
1Ningbo Institute of Innovation for Combined Medicine and Engineering (NIIME), The Affiliated LiHuili Hospital of Ningbo University, Ningbo, Zhejiang, 315100, People’s Republic of China; 2The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, 330006, People’s Republic of China; 3School of Materials Science and Chemical Engineering, Ningbo University, Ningbo, Zhejiang, 311215, People’s Republic of China; 4Department of Obstetrics and Gynecology, LiHuili Hospital Affiliated to Ningbo University, Ningbo, Zhejiang, 315040, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Fei Guo, Email lhlguofei@nbu.edu.cn Lingling Zhao, Email zhaolingling@nbu.edu.cn
Purpose: Current cervical cancer treatments have yet to realize significant advances in patient quality of life. To overcome the challenges of off-target toxicity and inefficient delivery, we developed targeted ROS-responsive selenium nanoparticles, based on selenium’s anticancer properties.
Methods: FA-ReRSeNPs were synthesized and subjected to systematic characterization of their physicochemical and biological properties. The anti-tumor activity of FA-ReRSeNPs, along with the mechanistic basis, was validated using integrated in vitro assays and in vivo animal models.
Results: Using human cervical cancer cells (Hela and SiHa) and a SiHa subcutaneous xenograft nude mouse model, we verified that FA-ReRSeNPs significantly reduced the selenium dose required for anticancer activity, while alleviating off-target damage to normal tissues. Mechanistic studies confirmed that FA-ReRSeNPs exert anticancer effects via inhibition of PI3K/AKT signaling pathway; this inhibition subsequently induces tumor cell apoptosis and restrains proliferation. Cross-validated results from in vitro assays and in vivo burden analyses demonstrate that FA-ReRSeNPs possess superior tumor-inhibitory potential with high targeting specificity.
Conclusion: This work confirms FA-ReRSeNPs as a precision-driven nanotherapeutic for cervical cancer management. The fusion of active targeting and ROS-responsive release mechanisms addresses the classic efficacy-toxicity dilemma of conventional anticancer agents, highlighting the translational value of intelligent nanoengineering in advancing cancer therapies.
Keywords: FA-ReRSeNPslenium, FA-ReRSeNPs, ROS-responsive delivery, cervical cancer, PI3K/AKT signaling pathway, targeted therapy